Transporter Cocktail

DRUG2 trials

Sponsors

Moleac Pte Ltd., Taiho Oncology, Inc.

Conditions

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsStroke

Phase 1

Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects

CompletedNCT04233437

Moleac Pte Ltd.Stroke

Start: 2020-02-10End: 2020-05-16Updated: 2020-09-03

Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

RecruitingNCT05967689

Taiho Oncology, Inc.Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Start: 2023-07-31End: 2028-12-31Target: 220Updated: 2026-09-01

Related Papers

REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (<i>EGFR</i>) mutations.

Journal of Clinical Oncology2024-06-011 citations